Janux Therapeutics (NASDAQ:JANX) Shares Up 5.5% on Analyst Upgrade

Posted by Brenda Bartman on Aug 26th, 2026

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX – Get Free Report) were up 5.5% on Monday after TD Cowen upgraded the stock to a strong-buy rating. The company traded as high as $18.26 and last traded at $18.3390. 220,342 shares were traded during mid-day trading, a decline of 80% from the average daily volume of 1,114,302 shares. The stock had previously closed at $17.39.

A number of other equities research analysts also recently commented on JANX. Wedbush decreased their target price on Janux Therapeutics from $45.00 to $36.00 and set an “outperform” rating for the company in a report on Friday, May 8th. Evercore set a $22.00 price target on shares of Janux Therapeutics in a research report on Monday, May 11th. Wolfe Research upgraded shares of Janux Therapeutics from a “peer perform” rating to an “outperform” rating and set a $23.00 price objective for the company in a research note on Monday. Stifel Nicolaus set a $35.00 price objective on shares of Janux Therapeutics in a report on Friday, August 7th. Finally, JonesTrading cut their price objective on shares of Janux Therapeutics from $50.00 to $28.00 and set a “buy” rating on the stock in a research note on Tuesday, April 28th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $36.46.

Read Our Latest Stock Analysis on JANX

Insider Activity at Janux Therapeutics

In related news, insider Janeen Noel Doyle sold 4,059 shares of the firm’s stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $14.03, for a total transaction of $56,947.77. Following the sale, the insider directly owned 75,941 shares of the company’s stock, valued at $1,065,452.23. This trade represents a 5.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 7.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Janux Therapeutics

Hedge funds have recently bought and sold shares of the stock. Rhenman & Partners Asset Management AB lifted its stake in shares of Janux Therapeutics by 125.1% in the 4th quarter. Rhenman & Partners Asset Management AB now owns 225,377 shares of the company’s stock valued at $3,110,000 after purchasing an additional 125,250 shares during the period. Y Intercept Hong Kong Ltd acquired a new stake in Janux Therapeutics during the first quarter valued at $1,946,000. Teachers Retirement System of The State of Kentucky purchased a new position in Janux Therapeutics in the fourth quarter valued at $536,000. Rangeley Capital LLC increased its holdings in Janux Therapeutics by 382.0% in the first quarter. Rangeley Capital LLC now owns 122,500 shares of the company’s stock valued at $1,703,000 after buying an additional 97,086 shares in the last quarter. Finally, Irenic Capital Management LP acquired a new position in shares of Janux Therapeutics in the first quarter worth about $10,645,000. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Stock Up 0.4%

The business’s 50-day simple moving average is $15.85 and its two-hundred day simple moving average is $14.70. The firm has a market cap of $1.14 billion, a price-to-earnings ratio of -11.39 and a beta of 2.50.

Janux Therapeutics (NASDAQ:JANX – Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.10). The firm had revenue of $10.27 million during the quarter, compared to analysts’ expectations of $19.07 million. On average, analysts expect that Janux Therapeutics, Inc. will post -1.76 earnings per share for the current year.

About Janux Therapeutics

(Get Free Report)

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.